Palvella Therapeutics Completes FDA Rolling Submission for QTORIN Rapamycin Application

Palvella Therapeutics has finished its rolling submission of a New Drug Application to the FDA seeking approval for QTORIN Rapamycin to treat microcystic lymphatic malformations.

31 Aug, 11:30 — 31 Aug, 11:30

Post Share

Sources

Showing 1 of 1 sources

taiwan-newsMostly Factual5d ago

Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations - Taiwan News

Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations Taiwan News

Read full article →

Palvella Therapeutics Completes FDA Rolling Submission for QTORIN Rapamycin Application

Sources

Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations - Taiwan News

Related Stories

Nigeria Closes Schools in Plateau State Over Diphtheria Outbreak

Singapore Air Quality Improves From Unhealthy to Moderate Levels

West Nile Virus Cases Surpass 1,000 Across Europe

Bangladesh Measles Epidemic Nears 1,000 Child Fatalities